Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience

CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation. OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial. DESIGN: A retrospect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Endocrinol Metab
Main Authors: Dadu, Ramona, Shah, Komal, Busaidy, Naifa L., Waguespack, Steven G., Habra, Mouhammad A., Ying, Anita K., Hu, Mimi I., Bassett, Roland, Jimenez, Camilo, Sherman, Steven I., Cabanillas, Maria E.
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2015
Assuntos:
JCEM Online: Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283003/
https://ncbi.nlm.nih.gov/pubmed/25353071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-2246
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados